The International Liver Congress 2014 (ILC 2014), the 49th annual meeting of the European Association for the Study of the Liver (EASL), took place in London, UK, 9-13th April 2014.

Conference highlights

New WHO guidelines

WHO recommends global use of newest hepatitis C drugs, urges price reductions

HIV and HCV co-infection

Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection

New EASL guidelines

European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs


aidsmap news from ILC 2014

← First1Next →

Editors' picks from other sources

News bulletins

Sign up for our email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

More hepatitis news

For more information on viral hepatitis visit infohep.org.

Infohep is a hepatitis project we're working on in partnership with the European Liver Patients Association (ELPA).

Visit infohep.org >

Official conference website

Find out more about the conference and view the programme on the official conference website.

Visit the conference website >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close